TY - JOUR T1 - Defining Remission in Psoriatic Arthritis: Are We Getting Closer? JF - The Journal of Rheumatology JO - J Rheumatol SP - 907 LP - 908 DO - 10.3899/jrheum.150331 VL - 42 IS - 6 AU - ENRIQUE R. SORIANO Y1 - 2015/06/01 UR - http://www.jrheum.org/content/42/6/907.abstract N2 - New paradigms in the management of psoriatic arthritis (PsA) are gaining great acceptance in the rheumatology community, including early treatment1, remission as a treatment objective2, assessment of all domains involved3, and frequent measuring of disease activity and adjusting therapy accordingly (treat to target)4.To achieve these goals, we need effective therapies. The introduction of biologic therapies, mainly tumor necrosis factor inhibitors (TNFi), has greatly improved our ability to treat the various manifestations of PsA.These various manifestations include peripheral and axial joint, skin, and nail involvement; enthesitis and dactylitis being among the more frequent ones. It is important to gather data for all these clinical features to assess disease activity. Remission criteria and activity indexes borrowed from rheumatoid arthritis (RA) have been used in PsA, but they clearly are unable to include all PsA manifestations2,5,6. Composite measures combine several dimensions of disease status, often by combining these different domains into a single score. Such indices seem to be more efficient than unidimensional instruments2,5,6. Composite measures, however, give rise to some concerns because a single measure that encompasses diverse domains might lose the ability to differentiate between activity in individual domains. At the OMERACT meeting (Outcome … Address correspondence to Dr. E.R. Soriano, Hospital Italiano de Buenos Aires, Sección Reumatología, Servicio de Clínica Médica, Gascon 450, Buenos Aires 1181, Argentina. E-mail: enrique.soriano{at}hospitalitaliano.org.ar ER -